Merck & Co., one of the pharmaceutical world’s stalwart giants, has just plunked down a staggering $10 billion to acquire Verona Pharma. At first glance, it’s a compelling story of Big Pharma gobbling up a biotech gem with a promising new COPD drug. But peel back the layers, and it becomes clear: this deal, while good, is just a single step. If Merck wants to future-proof its empire in the face of the looming Keytruda patent cliff, it will need to keep that M&A engine humming, hard and fast. The Keytruda Conundrum Let’s start with the obvious. Merck has been riding high on the back of Keytruda, its blockbuster immunotherapy cancer drug that brought in nearly $30 billion in revenue in 2024 alone. That’s almost half the company’s entire top line. The problem? Keytruda’s U.S. patent protection begins expiring in 2028, and with it goes the pricing power that’s been propping up Merck’s valuation for years. So what’s a pharma giant to do when its cash cow is approaching retirement ag...